In Part II, we take a personal look at the journey into PTSD Hell. We also examine the additional serious issues facing veterans attempting to cope with PTSD.
Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments
Mydecine announces an LOI to co-develop its own digital therapeutics platform, in partnership with Maya Health.
Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department
Optimi Health receives its Health Canada Dealers' License and initiates new Quality Assurance Department.
Cybin Provides 2021 Year End Summary
Cybin Inc provides a year-end update highlighting drug and IP development as well as international expansion.
The Year In Review For Psychedelic Drug Stocks: 2021
2021 was two different "years" for the psychedelic drug industry. Impressive progress in drug R&D and clinics; stocks pushed down to absurdly lean multiples.
COMPASS Selected for Addition to NASDAQ Biotechnology Index
Compass Pathways has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), tracking the performance of NASDAQ biotechnology/pharmaceutical companies.
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights
Awakn Life Sciences reports its Q3 for fiscal 2021. Highlights include key IP and clinic acquisitions, and the company's first revenues.
MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD
MindMed's Phase IIa clinical trial of LSD for adults ADHD is officially underway, enrolling patients.
MINDCURE Nears Finish Line With iSTRYM Commercialization
MINDCURE moves an important step closer to the full commercial deployment of its iSTRYM digital therapeutics platform, and also makes a key addition to its management team.
MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022
HIPAA compliance certification is the next step for the Company in working towards having the iSTRYM technology platform classified a ‘Software as a Medical Device’ by the FDA.
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
Cybin Inc receives its Notice of Allowance from the USPTO with respect to its patent for CYB004.
MindMed Appoints Robert Barrow as Chief Executive Officer and Director
MindMed announces that interim CEO Robert Barrow has now been named the permanent CEO, and added as a Director.
